Stomach cancer, though not as common as some other forms of cancer, can be a serious and life-threatening condition if not ...

Stomach cancer, though not as common as some other forms of cancer, can be a serious and life-threatening condition if not ...

Shares of ArriVent BioPharma rose after the company announced positive initial data from a Phase 1 trial of treatment for gastrointestinal cancers. The stock gained 9.3% to $22.95 in premarket trading ...

ArriVent BioPharma (NASDAQ:AVBP) delivered early oncology updates with initial Phase 1 results for ARR-217, an investigational antibody-drug conjugate targeting cadherin-17 (CDH17). The candidate, ...

A breakthrough treatment has made significant progress, showing promising results in decreasing recurrence and death from a ...

FDA approves Tukysa maintenance therapy with Herceptin and Perjeta, extending progression-free survival by over eight months ...

AstraZeneca ( AZN) said its experimental stomach cancer treatment doubled survival time in a late-stage clinical trial, ...

Two Phase 3 trials presented at Europe's leading oncology conference show major survival gains: Roche's divarasib outperforms ...

Global Fabry Disease Market size is expected to be worth around US$ 5.3 Billion by 2034 from US$ 2.5 Billion in 2024.

"Doctor, I've been taking this stomach medicine for about 10 years now. Is that okay?"I am often asked this during outpatient ...

GLP-1 receptor agonists support weight loss and metabolic control in people with inflammatory bowel disease, while ...

Using ultrasound images to monitor inflammatory bowel disease is catching on in the United States. Find out what it is, how ...